


**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A compound of formula I:



(I)

wherein:

**U** is O, S or NR<sup>2</sup>;

**s** is 0 or 1;

**X** is CO or SO<sub>2</sub>;

**Z** is O, S or NR<sup>4</sup>, wherein R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl and hydroxy-C<sub>3-8</sub>-cycloalk(en)yl;

**q** is 0 or 1;

**R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;






**R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl and cyano; provided that:

when **R**<sup>2</sup> is halogen or cyano, then **s** is 0; and

when  $s$  is 1 and  $U$  is  $NR^2$ , then  $R^2$  is selected from the group consisting of hydrogen,  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar, Ar- $C_{1-6}$ -alk(en/yn)yl, Ar- $C_{3-8}$ -cycloalk(en)yl, acyl, hydroxy- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl, halo- $C_{1-6}$ -alk(en/yn)yl and halo- $C_{3-8}$ -cycloalk(en)yl; or  $R^2$  and  $R^2'$  together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;

$R^3$  is selected from the group consisting of  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl,  $C_{3-8}$ -cycloalk(en)yl- $C_{1-6}$ -alk(en/yn)yl, Ar, Ar- $C_{1-6}$ -alk(en/yn)yl, Ar- $C_{3-8}$ -cycloalk(en)yl, hydroxy- $C_{1-6}$ -alk(en/yn)yl, hydroxy- $C_{3-8}$ -cycloalk(en)yl, halo- $C_{1-6}$ -alk(en/yn)yl and halo- $C_{3-8}$ -cycloalk(en)yl; and

$Y$  represents a group of formulae-formula **VI**, **VII**, **VIII**, **IX** or **XXX**:



wherein:

$W$  is O or S;

$a$  is 0, 1, 2 or 3;

$b$  is 0, 1, 2, 3 or 4;

**c** is 0 or 1;

**d** is 0, 1, 2 or 3;

**e** is 0, 1 or 2;

**f** is 0, 1, 2, 3, 4 or 5;

**g** is 0, 1, 2, 3 or 4;

**h** is 0, 1, 2 or 3; and

each **R**<sup>5</sup> is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(an/en/yn)yloxy, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl, -CO-NR<sup>6</sup>R<sup>6</sup>, cyano, nitro, -NR<sup>7</sup>R<sup>7</sup>, -S-R<sup>8</sup>, -SO<sub>2</sub>R<sup>8</sup> and SO<sub>2</sub>OR<sup>8</sup>; or two **R**<sup>5</sup> substituents together with the carbon atoms to which they are attached form a 5-8 membered ring which optionally contains one or two heteroatoms; wherein:

**R**<sup>6</sup> and **R**<sup>6</sup>' are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and Ar;

**R**<sup>7</sup> and **R**<sup>7</sup>' are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and acyl; and

**R**<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and -NR<sup>9</sup>R<sup>9</sup>; wherein:

**R**<sup>9</sup> and **R**<sup>9</sup>' are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; with the provisos that:

when **R**<sup>5</sup> is SO<sub>2</sub>OR<sup>8</sup>, then **R**<sup>8</sup> is not -NR<sup>9</sup>R<sup>9</sup>; and

when **R**<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>[[ ]], then **R**<sup>8</sup> is not a hydrogen atom;

or salts thereof;

with the proviso that the compound of formula I is not:

N-[4-[(4-aminophenyl)amino]methyl]phenyl]-acetamide;

N-[4-[(4-amino-2-methylphenyl)amino]methyl]phenyl]-acetamide;

N-[4-[(4-amino-3-methylphenyl)amino]methyl]phenyl]-acetamide;

2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)-benzamide;

N-[4-[(3,4,5-trimethoxyphenyl)amino]methyl]phenyl]-acetamide;

N-[4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2- naphthalenyl)amino]methyl]phenyl]-acetamide;

N-[4-[[3-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[2-(1H-imidazol-1-ylmethyl)phenyl]amino]methyl]phenyl]-acetamide;

N-[4-[(4-amino-3,5-dichlorophenyl)amino]methyl]phenyl]- acetamide;

N-[4-[(2,4-diamino-6-quinazolinyl)amino]methyl]phenyl]- acetamide; or

N-[4-[(2,4-diamino-6-quinazolinyl)amino]methyl]phenyl]- acetamide.

2. (Previously presented) A compound according to claim 1, wherein  $\mathbf{R}^1$  and  $\mathbf{R}^{1'}$  are independently selected from the group consisting of hydrogen and  $\text{C}_{1-6}\text{-alk(en/yn)yl}$ .
3. (Currently amended) A compound according to claim 2, wherein at least one of  $\mathbf{R}^1$  and  $\mathbf{R}^{1'}$  is a hydrogen-atom.
4. (Previously presented) A compound according to claim 1, wherein  $s$  is 1.
5. (Previously presented) A compound according to claim 1, wherein  $s$  is 0.
6. (Previously presented) A compound according to claim 1, wherein  $\mathbf{R}^2$  is selected from the group consisting of hydrogen,  $\text{C}_{1-6}\text{-alk(en/yn)yl}$ , Ar and halogen, provided that when  $\mathbf{R}^2$  is halogen, then  $s$  is 0.
7. (Currently amended) A compound according to claim 4, wherein  $\mathbf{U}$  is  $\mathbf{N}\mathbf{R}^{2'}$  and at least one of  $\mathbf{R}^2$  and  $\mathbf{R}^{2'}$  is a hydrogen-atom.
8. (Currently amended) A compound according to claim 7, wherein both  $\mathbf{R}^2$  and  $\mathbf{R}^{2'}$  are hydrogen atoms.
9. (Previously presented) A compound according to claim 1, wherein  $\mathbf{X}$  is CO.

10. (Previously presented) A compound according to claim 1, wherein  $q$  is 0.
11. (Previously presented) A compound according to claim 1, wherein  $q$  is 1.
12. (Currently amended) A compound according to claim 11, wherein  $Z$  is an oxygen atom.
13. (Previously presented) A compound according to claim 1, wherein  $R^3$  is  $C_{1-6}$ -alk(en/yn)yl.
14. (Currently amended) A compound according to claim 1, wherein  $Y$  represents a group of formulae formula IX or XXX.
15. (Currently amended) A compound according to claim 1, wherein each  $R^5$  is independently selected from the group consisting of a  $C_{1-6}$ -alk(en/yn)yl,  $C_{3-8}$ -cycloalk(en)yl, Ar, cyano, halogen, halo- $C_{1-6}$ -alk(en/yn)yl and  $C_{1-6}$ -alk(an/en/yn)yloxy; or two adjacent  $R^5$  substituents together with the carbon atoms to which they are attached form a 5-8 membered ring which optionally contains one or two heteroatoms.
16. (Currently amended) A compound selected from the group consisting of:
  - {2-Amino-4-[(4-tert-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
  - (2-Amino-4-phenylaminomethyl-phenyl)-carbamic acid ethyl ester;
  - [2-Amino-4-(naphthalen-2-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;
  - [2-Amino-4-(p-tolylamino-methyl)-phenyl]-carbamic acid ethyl ester;
  - {2-Amino-4-[(4-trifluoromethylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
  - {2-Amino-4-[(4-chlorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
  - {2-Amino-4-[(3-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
  - {2-Amino-4-[(4-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
  - {2-Amino-4-[(2-fluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
  - [2-Amino-4-(biphenyl-4-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;
  - {2-Amino-4-[(2,4-difluorophenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;
  - {2-Amino-4-[(4-methoxyphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-cyclohexylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;

[2-Amino-4-(indan-5-ylaminomethyl)-phenyl]-carbamic acid ethyl ester;

{2-Amino-4-[(4-isopropylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-butylphenylamino)-methyl]-phenyl}-carbamic acid ethyl ester;

{2-Amino-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(2,4-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(2,3-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(3,5-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(3,4-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(3-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(3-fluoro-4-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(3,4-difluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(4-cyanophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(4-fluoro-3-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(3-chloro-4-methylphenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[(3-chlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

[2-Amino-4-(m-tolylaminomethyl)phenyl]carbamic acid ethyl ester;

{2-Amino-4-[1-(4-chlorophenylamino)ethyl]phenyl} carbamic acid ethyl ester;

{2-Amino-4-[1-(4-trifluoromethylphenylamino)ethyl]phenyl} carbamic acid ethyl ester;

N-{2-Amino-4-[(3-fluorophenylamino)methyl]phenyl}-2,2-dimethylpropionamide;

{4-[(4-Chlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{4-[(4-Trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;

{4-[1-(4-Chlorophenylamino)ethyl]phenyl} carbamic acid ethyl ester;

{4-[(4-Fluorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;

{4-[(4-Chlorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;

{2-Methyl-4-[(4-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;

{4-[(3,4-Difluorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;

{4-[(3-Fluorophenylamino)methyl]-2-methylphenyl} carbamic acid ethyl ester;

{2-Chloro-4-[(4-chlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Chloro-4-[(4-trifluoromethyl-phenylamino)-methyl]-phenyl} -carbamic acid ethyl ester;

{2-Chloro-4-[(4-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Chloro-4-[(3-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{2-Chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl} carbamic acid ethyl ester;

{4-[(4-Chlorophenylamino)methyl]-2-fluorophenyl} carbamic acid ethyl ester;

{4-[(4-Chloro-3-fluorophenylamino)methyl]-2-fluorophenyl} carbamic acid ethyl ester;

{2-Fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl} carbamic acid ethyl ester;

{4'-Dimethylamino-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;

{4'-Dimethylamino-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;

{4'-Chloro-5-[(3-fluorophenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;

{4'-Chloro-5-[(4-trifluoromethylphenylamino)methyl]biphenyl-2-yl} carbamic acid ethyl ester;

N-{4-[(4-chlorophenylamino)methyl]phenyl} butyramide;

N-{4-[(3,4-dichlorophenylamino)methyl]phenyl} butyramide;

N-{4-[(4-chloro-3-fluorophenylamino)methyl]phenyl} butyramide;

N-{4-[(4-fluoro-phenylamino)methyl]-2-methylphenyl} butyramide;

N-{4[(3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;

N-{4-[(4-chlorophenylamino)methyl]-2-methylphenyl}butyramide;

N-{4-[(3,4-dichlorophenylamino)methyl]-2-methylphenyl}butyramide;

N-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-methylphenyl}butyramide;

N-{2-chloro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;

N-{2-chloro-4-[(4-fluorophenylamino)methyl]phenyl}butyramide;

N-{2-chloro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;

N-{2-chloro-4-[(4-chlorophenylamino)methyl]phenyl}butyramide;

N-{2-chloro-4-[(3,4-dichlorophenylamino)methyl]phenyl}butyramide;

N-{2-chloro-4-[(4-chloro-3-fluorophenylamino)methyl]phenyl}butyramide;

N-{2-fluoro-4-[(3-fluorophenylamino)methyl]phenyl}butyramide;

N-{4-[(4-chlorophenylamino)methyl]-2-fluorophenyl}butyramide;


N-{2-fluoro-4-[(4-trifluoromethylphenylamino)methyl]phenyl}butyramide;

N-{4-[(3,4-dichlorophenylamino)methyl]-2-fluorophenyl}butyramide; and

N-{4-[(4-chloro-3-fluorophenylamino)methyl]-2-fluorophenyl}butyramide; or

a salt thereof.

17. (Currently amended) A pharmaceutical composition comprising a compound formula I:



wherein:

**U** is O, S or NR<sup>2</sup>'[[ ]];

**s** is 0 or 1;

**X** is CO or SO<sub>2</sub>;

**Z** is O, S or NR<sup>4</sup>, wherein R<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl and hydroxy-C<sub>3-8</sub>-cycloalk(en)yl;

**q** is 0 or 1;

**R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;






**R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl and cyano; provided that:

when **R**<sup>2</sup> is halogen or cyano, then **s** is 0;

when **s** is 1 and **U** is NR<sup>2</sup>', then **R**<sup>2</sup>' is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl; or **R**<sup>2</sup> and **R**<sup>2</sup>' together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;

**R**<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl; and

**Y** represents a group of formulae **VI**, **VII**, **VIII**, **IX** or **XXX**:



wherein:

**W** is O or S;

**a** is 0, 1, 2 or 3;

**b** is 0, 1, 2, 3 or 4;

**c** is 0 or 1;

**d** is 0, 1, 2 or 3;

**e** is 0, 1 or 2;

**f** is 0, 1, 2, 3, 4 or 5;

**g** is 0, 1, 2, 3 or 4;

**h** is 0, 1, 2 or 3; and

each **R**<sup>5</sup> is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(an/en/yn)yloxy, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl, -CO-NR<sup>6</sup>R<sup>6</sup>, cyano, nitro, -NR<sup>7</sup>R<sup>7</sup>, -S-R<sup>8</sup>,

-SO<sub>2</sub>R<sup>8</sup> and SO<sub>2</sub>OR<sup>8</sup>; or two R<sup>5</sup> substituents together with the carbon atoms to which they are attached form a 5-8 membered ring which optionally contains one or two heteroatoms; wherein:

R<sup>6</sup> and R<sup>6</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and Ar;

R<sup>7</sup> and R<sup>7</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and acyl; and

R<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and -NR<sup>9</sup>R<sup>9</sup>; wherein:

R<sup>9</sup> and R<sup>9</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; with the provisos that:

when R<sup>5</sup> is SO<sub>2</sub>OR<sup>8</sup>, then R<sup>8</sup> is not -NR<sup>9</sup>R<sup>9</sup>; and

when R<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>[[ ]], then R<sup>8</sup> is not a hydrogen atom;

or a pharmaceutically acceptable salt thereof; and

one or more pharmaceutically acceptable carriers or diluents, with the proviso that the compound of formula I is not:

2-[[[4-(acetylamino)phenyl]methyl]amino]-5-chloro-N-(5-chloro-2-pyridinyl)-benzamide;

N-[4-[[[3,4,5-trimethoxyphenyl]amino]methyl]phenyl]-acetamide;

N-[4-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl]amino]methyl]phenyl]-acetamide;

N-[4-[[[3-(1H-imidazol-1-yl)methyl]phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[2-(1H-imidazol-1-yl)methyl]phenyl]amino]methyl]phenyl]-acetamide;


N-[4-[[[4-(1H-imidazol-1-yl)methyl]phenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[4-amino-3,5-dichlorophenyl]amino]methyl]phenyl]- acetamide;

N-[4-[[[2,4-diamino-6-quinazolinyl]amino]methyl]phenyl]- acetamide; or

N-[4-[[[2,4-diamino-6-quinazolinyl]amino]methyl]phenyl]- acetamide.

18. (Withdrawn-currently amended) A method of increasing ion flow in a potassium channel of a mammal, comprising administering to said mammal a compound of formula I:



wherein:

**U** is O, S or **NR**<sup>2</sup>[[ ]];

**s** is 0 or 1;

**X** is CO or SO<sub>2</sub>;

**Z** is O, S or **NR**<sup>4</sup>, wherein **R**<sup>4</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl and hydroxy-C<sub>3-8</sub>-cycloalk(en)yl;

**q** is 0 or 1;

**R**<sup>1</sup> and **R**<sup>1'</sup> are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;

**R**<sup>2</sup> is selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl, halo-C<sub>3-8</sub>-cycloalk(en)yl and cyano; provided that:

when **R**<sup>2</sup> is halogen or cyano, then **s** is 0;


when **s** is 1 and **U** is **NR**<sup>2</sup>, then **R**<sup>2</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl,

Ar-C<sub>3-8</sub>-cycloalk(en)yl, acyl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl; or R<sup>2</sup> and R<sup>2</sup> together with the nitrogen atom to which they are attached form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;


R<sup>3</sup> is selected from the group consisting of C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar, Ar-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>3-8</sub>-cycloalk(en)yl, hydroxy-C<sub>1-6</sub>-alk(en/yn)yl, hydroxy-C<sub>3-8</sub>-cycloalk(en)yl, halo-C<sub>1-6</sub>-alk(en/yn)yl and halo-C<sub>3-8</sub>-cycloalk(en)yl;

and


Y represents a group of formulae VI, VII, VIII, IX or XXX:




VI




VII



VIII



IX



XXX

wherein:

W is O or S;

a is 0, 1, 2 or 3;

**b** is 0, 1, 2, 3 or 4;

**c** is 0 or 1;

**d** is 0, 1, 2 or 3;

**e** is 0, 1 or 2;

**f** is 0, 1, 2, 3, 4 or 5;

**g** is 0, 1, 2, 3 or 4;

**h** is 0, 1, 2 or 3; and

each **R**<sup>5</sup> is independently selected from the group consisting of a C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, Ar, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar-C<sub>1-6</sub>-alk(en/yn)yl, acyl, C<sub>1-6</sub>-alk(an/en/yn)yloxy, halogen, halo-C<sub>1-6</sub>-alk(en/yn)yl, -CO-NR<sup>6</sup>R<sup>6</sup>, cyano, nitro, -NR<sup>7</sup>R<sup>7</sup>, -S-R<sup>8</sup>, -SO<sub>2</sub>R<sup>8</sup> and SO<sub>2</sub>OR<sup>8</sup>; or two **R**<sup>5</sup> substituents together with the carbon atoms to which they are attached form a 5-8 membered ring which optionally contains one or two heteroatoms; wherein:

**R**<sup>6</sup> and **R**<sup>6</sup>' are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl and Ar;

**R**<sup>7</sup> and **R**<sup>7</sup>' are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and acyl; and

**R**<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl, C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl, Ar and -NR<sup>9</sup>R<sup>9</sup>; wherein **R**<sup>9</sup> and **R**<sup>9</sup>' are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>-alk(en/yn)yl, C<sub>3-8</sub>-cycloalk(en)yl and C<sub>3-8</sub>-cycloalk(en)yl-C<sub>1-6</sub>-alk(en/yn)yl; with the provisos that:

when **R**<sup>5</sup> is SO<sub>2</sub>OR<sup>8</sup>, then **R**<sup>8</sup> is not -NR<sup>9</sup>R<sup>9</sup>; and

when **R**<sup>5</sup> is SO<sub>2</sub>R<sup>8</sup>[[ ]], then **R**<sup>8</sup> is not a-hydrogen-atom; or

salts thereof.

19. (Withdrawn-currently amended) The method of claim 18, wherein administration of said compound is for the prevention, treatment or inhibition of a disorder or condition being responsive to an increased ion flow in a potassium channel.

20. (Withdrawn-currently amended) The method of claim 19, wherein the disorder or condition is a seizure disorder.
21. (Withdrawn-currently amended) The method of claim 19, wherein the disorder or condition is selected from the group consisting of neuropathic and migraine pain disorders.
22. (Withdrawn-currently amended) The method of claim 19, wherein the disorder or condition is an anxiety disorder.
23. (Withdrawn-currently amended) The method of claim 19, wherein the disorder or condition is a neurodegenerative disorder.
24. (Withdrawn-currently amended) The method of claim 19, wherein the disorder or condition is a neuronal hyperexcitation state.
25. (Withdrawn-currently amended) The method of claim 18, wherein the mammal is a human.
26. (Withdrawn-currently amended) The method of claim 19, wherein the disorder or condition is a disorder or condition of the central nervous system.
27. (Withdrawn-currently amended) The method of claim 20, wherein the seizure disorder is selected from the group consisting of convulsions, epilepsy and status epilepticus.
28. (Withdrawn-currently amended) The method of claim 21, wherein the neuropathic or migraine pain disorder is selected from the group consisting of allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy and neuropathic pain related to migraine.
29. (Withdrawn-currently amended) The method of claim 22, wherein the anxiety disorder is selected from the group consisting of anxiety, generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, social phobia, performance anxiety, post-traumatic stress disorder, acute stress reaction, adjustment disorders, hypochondriacal disorders, separation anxiety disorder, agoraphobia, specific phobias, anxiety disorder due to general medical condition and substance-induced anxiety disorder.
30. (Withdrawn-currently amended) The method of claim 23, wherein the neurodegenerative disorder is selected from the group consisting of Alzheimer's disease, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-induced encephalopathy and other

~~infection-related encephalopathies being caused by rubella viruses, herpes viruses, borrelia and by unknown pathogens, a non-AIDS-induced encephalopathy, Creutzfeld-Jakob disease, Parkinson's disease, and a trauma-induced neurodegeneration-neurodegenerations.~~

31. (Withdrawn-currently amended) The method of claim 24, wherein the neuronal hyperexcitation state is due to medicament withdrawal or intoxication.